Explore the vast range of titles available.

In the asymptotic theory of quantum hypothesis testing, the minimal error probability of the first kind jumps sharply from zero to one when the error exponent of the second kind passes by the point of the relative entropy of the two states in an increasing way. This is well known as the direct part and strong converse of quantum Stein's lemma. Here we look into the behavior of this sudden change and have make it clear how the error of first kind grows smoothly according to a lower order of the error exponent of the second kind, and hence we obtain the second-order asymptotics for quantum hypothesis testing. This actually implies quantum Stein's lemma as a special case. Meanwhile, our analysis also yields tight bounds for the case of finite sample size. These results have potential applications in quantum information theory. Our method is elementary, based on basic linear algebra and probability theory. It deals with the achievability part and the optimality part in a unified fashion.

We consider the problem of testing multiple quantum hypotheses $\\left\\{ {\\rho _1^{ \\otimes n},...,\\rho _r^{ \\otimes n}} \\right\\}$, where an arbitrary prior distribution is given and each of the r hypotheses is n copies of a quantum state. It is known that the minimal average error probability Pe decays exponentially to zero, that is, Pe = exp{–ξn + 0(n)}. However, this error exponent ξ is generally unknown, except for the case that r = 2. In this paper, we solve the long-standing open problem of identifying the above error exponent, by proving Nussbaum and Szkola's conjecture that ξ = mini≠j C(ρi, ρj). The right-hand side of this equality is called the multiple quantum Chernoff distance, and $C\\left( {{\\rho _i},{\\rho _j}} \\right): = \\max {}_{0 \\leqslant s \\leqslant 1}\\left\\{ { - \\log Tr\\rho _i^s\\rho _j^{1 - s}} \\right\\}$ has been previously identified as the optimal error exponent for testing two hypotheses, $\\rho _i^{ \\otimes n}$ versus $\\rho _j^{ \\otimes n}$. The main ingredient of our proof is a new upper bound for the average error probability, for testing an ensemble of finite-dimensional, but otherwise general, quantum states. This upper bound, up to a states-dependent factor, matches the multiple-state generalization of Nussbaum and Szkola's lower bound. Specialized to the case r = 2, we give an alternative proof to the achievability of the binary-hypothesis Chernoff distance, which was originally proved by Audenaert et al.

We report a 2-family cluster of persons infected with severe acute respiratory syndrome coronavirus 2 in the city of Zhoushan, Zhejiang Province, China, during January 2020. The infections resulted from contact with an infected but potentially presymptomatic traveler from the city of Wuhan in Hubei Province.

Single‐component emitters with stable and bright warm white‐light emission are highly desirable for high‐efficacy warm white light‐emitting diodes (warm‐WLEDs), however, materials with such luminescence properties are extremely rare. Low­dimensional lead (Pb) halide perovskites can achieve warm white photoluminescence (PL), yet they suffer from low stability and PL quantum yield (PLQY). While Pb‐free air‐stable perovskites such as Cs2AgInCl6 emit desirable warm white light, sophisticated doping strategies are typically required to increase their PL intensity. Moreover, the use of rare metal‐bearing compounds along with the typically required vacuum‐based thin‐film processing may greatly increase their production cost. Herein, organic–inorganic hybrid cuprous (Cu+)‐based metal halide MA2CuCl3 (MA = CH3NH3+) that meets the requirements of i) nontoxicity, ii) high PLQY, and iii) dopant‐free is presented. Both single crystals and thin films of MA2CuCl3 can be facilely prepared by a low‐cost solution method, which demonstrate bright warm white‐light emission with intrinsically high PLQYs of 90–97%. Prototype electroluminescence devices and down‐conversion LEDs are fabricated with MA2CuCl3 thin films and single crystals, respectively, which show bright luminescence with decent efficiencies and operational stability. These findings suggest that MA2CuCl3 has a great potential for the single‐component indoor lighting and display applications. The newly developed hybrid MA2CuCl3 meets the requirements of i) broadband warm white‐light emission, ii) nontoxicity, iii) high photoluminescence quantum yield, iv) dopant‐free, v) low‐cost, and vi) excellent film‐forming ability. Besides, the first successful electroluminescence application of MA2CuCl3 opens a new avenue toward single‐component warm white light‐emitting diodes.

Research in finance and macroeconomics has routinely employed multiple horizons to test asset return predictability. In a simple predictive regression model, we find the popular scaled test can have zero power when the predictor is not sufficiently persistent. A new test based on implication of the short-run model is suggested and is shown to be uniformly more powerful than the scaled test. The new test can accommodate multiple predictors. Compared with various other widely used tests, simulation experiments demonstrate remarkable finite-sample performance. We reexamine the predictive ability of various popular predictors for aggregate equity premium.

The diverse expression pattern of CD36 reflects its multiple cellular functions. However, the roles of CD36 in colorectal cancer (CRC) remain unknown. Here, we discover that CD36 expression is progressively decreased from adenomas to carcinomas. CD36 loss predicts poor survival of CRC patients. In CRC cells, CD36 acts as a tumor suppressor and inhibits aerobic glycolysis in vitro and in vivo. Mechanically, CD36-Glypcian 4 (GPC4) interaction could promote the proteasome-dependent ubiquitination of GPC4, followed by inhibition of β-catenin/c-myc signaling and suppression of downstream glycolytic target genes GLUT1, HK2, PKM2 and LDHA. Moreover, disruption of CD36 in inflammation-induced CRC model as well as Apc Min/+ mice model significantly increased colorectal tumorigenesis. Our results reveal a CD36-GPC4-β-catenin-c-myc signaling axis that regulates glycolysis in CRC development and may provide an intervention strategy for CRC prevention. CD36 is a membrane glycoprotein that has been shown to have tumour promoting or suppressor function depending on tumour type. Here, the authors address CD36 function in colorectal cancer and show it acts as a tumour suppressor by inhibiting B-catenin/myc signalling, resulting in downregulation of glycolysis.

Background Immune system evasion, distance tumor metastases, and increased cell proliferation are the main reasons for the progression of non-small cell lung cancer (NSCLC) and the death of NSCLC patients. Dysregulation of circular RNAs plays a critical role in the progression of NSCLC; therefore, further understanding the biological mechanisms of abnormally expressed circRNAs is critical to discovering novel, promising therapeutic targets for NSCLC treatment. Methods The expression of circular RNA fibroblast growth factor receptor 1 (circFGFR1) in NSCLC tissues, paired nontumor tissues, and cell lines was detected by RT-qPCR. The role of circFGFR1 in NSCLC progression was assessed both in vitro by CCK-8, clonal formation, wound healing, and Matrigel Transwell assays and in vivo by a subcutaneous tumor mouse assay. In vivo circRNA precipitation, RNA immunoprecipitation, and luciferase reporter assays were performed to explore the interaction between circFGFR1 and miR-381-3p. Results Here, we report that circFGFR1 is upregulated in NSCLC tissues, and circFGFR1 expression is associated with deleterious clinicopathological characteristics and poor prognoses for NSCLC patients. Forced circFGFR1 expression promoted the migration, invasion, proliferation, and immune evasion of NSCLC cells. Mechanistically, circFGFR1 could directly interact with miR-381-3p and subsequently act as a miRNA sponge to upregulate the expression of the miR-381-3p target gene C-X-C motif chemokine receptor 4 (CXCR4), which promoted NSCLC progression and resistance to anti-programmed cell death 1 (PD-1)- based therapy. Conclusion Taken together, our results suggest the critical role of circFGFR1 in the proliferation, migration, invasion, and immune evasion abilities of NSCLC cells and provide a new perspective on circRNAs during NSCLC progression.

Major depressive disorder is a devastating psychiatric disease that afflicts up to 17% of the world’s population. Postmortem brain analyses and imaging studies of patients with depression have implicated basal lateral amygdala (BLA) dysfunction in the pathophysiology of depression. However, the circuit and molecular mechanisms through which BLA neurons modulate depressive behavior are largely uncharacterized. Here, in mice, we identified that BLA cholecystokinin (CCK) glutamatergic neurons mediated negative reinforcement via D2 medium spiny neurons (MSNs) in the nucleus accumbens (NAc) and that chronic social defeat selectively potentiated excitatory transmission of the CCKBLA–D2NAc circuit in susceptible mice via reduction of presynaptic cannabinoid type-1 receptor (CB1R). Knockdown of CB1R in the CCKBLA–D2NAc circuit elevated synaptic activity and promoted stress susceptibility. Notably, selective inhibition of the CCKBLA–D2NAc circuit or administration of synthetic cannabinoids in the NAc was sufficient to produce antidepressant-like effects. Overall, our studies reveal the circuit and molecular mechanisms of depression.Activating cannabinoid receptors in a newly identified neural circuit ameliorates depressive-like behaviors in mice.

Background Existing clinical studies supported the potential efficacy of mesenchymal stromal cells as well as derived exosomes in the treatment of COVID-19. We aimed to explore the safety and efficiency of aerosol inhalation of the exosomes derived from human adipose-derived MSCs (haMSC-Exos) in patients with COVID-19. Methods The MEXCOVID trial is a phase 2a single-arm, open-labelled, interventional trial and patients were enrolled in Jinyintan Hospital, Wuhan, China. Eligible 7 patients were assigned to receive the daily dose of haMSCs-Exos (2.0 × 10 8 nano vesicles) for consecutively 5 days. The primary outcomes included the incidence of prespecified inhalation-associated events and serious adverse events. We also observed the demographic data, clinical characteristics, laboratory results including lymphocyte count, levels of D-dimer and IL-6 as well as chest imaging. Results Seven severe COVID-19 related pneumonia patients (4 males and 3 females) were enrolled and received nebulized haMSC-Exos. The median age was 57 year (interquartile range (IQR), 43 year to 70 year). The median time from onset of symptoms to hospital admission and administration of nebulized haMSC-Exos was 30 days (IQR, 15 days to 40 days) and 54 d (IQR, 34 d to 69 d), respectively. All COVID-19 patients tolerated the haMSC-Exos nebulization well, with no evidence of prespecified adverse events or clinical instability during the nebulization or during the immediate post-nebulization period. All patients presented a slight increase of serum lymphocyte counts (median as 1.61 × 10 9 /L vs. 1.78 × 10 9 /L). Different degrees of resolution of pulmonary lesions after aerosol inhalation of haMSC-Exos were observed among all patients, more obviously in 4 of 7 patients. Conclusions Our trial shows that a consecutive 5 days inhalation dose of clinical grade haMSC-Exos up to a total amount of 2.0 × 10 9 nano vesicles was feasible and well tolerated in seven COVID-19 patients, with no evidence of prespecified adverse events, immediate clinical instability, or dose-relevant toxicity at any of the doses tested. This safety profile is seemingly followed by CT imaging improvement within 7 days. Further trials will have to confirm the long-term safety or efficacy in larger population. Trial Registration : MEXCOVID, NCT04276987.

As one of the most appealing strategies for the synthesis of nanomaterials with various architectures, emulsion-directed methods have been rarely used to control the structure of metal-organic frameworks (MOFs). Herein, we report a versatile salt-assisted nanoemulsion-guided assembly to achieve continuous architecture transition of hierarchical Zr-based MOFs. The morphology of nanoemulsion can be facilely regulated by tuning the feed ratio of a dual-surfactant and the introduced amount of compatible hydrophobic compounds, which directs the assembly of MOFs with various architectures such as bowl-like mesoporous particle, dendritic nanospheres, walnut-shaped particles, crumpled nanosheets and nanodisks. The developed dendritic nanospheres with highly open and large mesochannels is successfully used as matrix for the co-immobilization of coenzymes and corresponding enzymes to realize the in situ heterogeneous regeneration of NAD + . This strategy is expected to pave a way for exploring sophisticated hierarchical MOFs which can be competent for practical applications with bulk molecules involved. Controlling the structure of hierarchical metal-organic frameworks via soft template remains a challenge. Here, the authors report a salt-assisted nanoemulsion-guided strategy to achieve continuous structure transition of hierarchical Zr-based MOFs.